Two-phase Ia/Ib open-label, dose-escalation, and expansion studies are currently recruiting participants to evaluate the safety and efficacy of XmAb541 and CTIM-76, a humanized T-cell-engaging bsAbs targeting CLDN6, in subjects with platinum-resistant ovarian cancer and other advanced CLDN6-positive solid tumors, including testicular and endometrial cancers (NCT06276491, NCT06515613). Here, CLDN6 is linked to ovarian cancer.